Kangstem Biotech강스템바이오텍

Kangstem Biotech's revenue has shrunk sharply while losses remain deep, with the stock well below its 52-week high.

Kangstem Biotech, a KOSDAQ-listed stem cell therapy and cosmetics developer, reported trailing twelve-month revenue of ₩3.0B against an operating loss of ₩19.1B to the half-year of 2026. Revenue fell 53.9% in 2025 after a strong 2024, and the company has posted operating losses in every year shown since 2021. The share price closed at ₩1,966 on 21 October 2026, about 58% below its 52-week high of ₩4,690, though it is still up 39.5% over one year.

What stands out

• Trailing revenue is ₩3.0B with an operating loss of ₩19.1B, an operating margin of -630%, so costs are far above sales.
• Free cash flow is -₩17.0B and borrowings are ₩7.6B against cash of ₩0.9B, which points to a reliance on funding beyond operations.
• The data's discounted cash flow model gives a base fair value of ₩138 per share, well below the current price; the data does not explain the assumptions behind it.
• Foreign ownership fell from 3.2% to 2.1% over the past 60 days, while retail investors were net buyers over the last 20 days.
• Recent filings include a half-year report, quarterly report, and several investor relations events and management-related disclosures, but the data does not include details of their content, and news headlines are absent.

What to watch

• The next results and filings, including any update on revenue recovery and cash burn versus the ₩7.6B of borrowings.
• The management-related disclosures filed in July 2026 and any follow-up filings, since their content is not in the data.
• Price swings: the stock is down 12.6% over three months and sits far below its 52-week high.